Main financial assets discussed:
1. Organon & Co. (NYSE:OGN) - the pharmaceutical company formed through a spinout from Merck & Co.
2. Viatris (VTRS) - a new entity formed through a spinout from Pfizer's Established Brands division.
3. Haleon (HLN) - a new entity formed through a spinout from GSK's Consumer Health division.
4. Kenvue (KVUE) - the new name for Johnson & Johnson's spun-out Consumer Health division.
5. EUROAPI - the new business formed through a spinout from Sanofi's drug ingredients business.
Top 3 key points:
1. Organon's Women's Health division has shown growth, driven by acquisitions and the success of its contraceptive product Nexplanon.
2. The biosimilars division has shown some growth, but the success of its key asset Hadlima, a biosimilar for AbbVie's Humira, is uncertain.
3. The Established Brands division remains the most valuable for Organon, but its performance is flat or declining.
Recommended actions:
- **Hold** Organon stock for now, especially with improved performance forecast for the second half of the year and greater cash flow generation.
- Watch Hadlima and Nexplanon sales closely.
- Hope for positive surprises within Organon's pipeline that could avert the need for further M&A spending.
Freedom Capital Markets Chief Global Strategist Jay Woods discusses his top health care stock picks, including UnitedHealth, Merck & Company, Johnson & Johnson, and Amgen, due to their presence in the Dow Jones Industrial Average and the continued strength of the health care sector. Woods also highlights the safety of health care as a sector and the positive technical trends observed in these stocks.
Johnson & Johnson's exchange offer for Kenvue shares was highly successful, with participating investors converting less than a quarter of their J&J stock into Kenvue shares.
Johnson & Johnson revises its financial guidance after spinning out Kenvue, but maintains its dividend and anticipates faster revenue growth.
Johnson & Johnson (JNJ) closed at $160.48, down 0.74%, with analysts revising EPS estimates lower, a potentially negative sign for the company's business outlook.
Certain stocks, such as Abbott Laboratories, Johnson & Johnson, and Coca-Cola, possess strong brands, diverse portfolios, and reliable dividends, making them excellent investments regardless of market conditions.
Johnson & Johnson is rebranding with a new logo that reflects its focus on pharmaceuticals and medical devices, replacing its long-used signature script with a modern design.
Investors should consider buying Coca-Cola (KO) and Johnson & Johnson (JNJ) as both companies offer solid balance sheets, strong dividend programs, and are recognized blue chip dividend stocks.
Johnson & Johnson stock rises as the pharmaceutical company boosts its full-year guidance after beating third-quarter earnings expectations.
Johnson & Johnson raised its profit forecast for 2023 in its first earnings report since spinning off its consumer health business, with the company's focus now on blockbuster drugs like Stelara.
J&J, a top-rated dividend stock with a strong financial rating, is seen as a good long-term investment option with better growth potential compared to overvalued stocks, despite concerns about missed opportunities in GLP-1 drugs and its impact on cardiovascular and joint replacement businesses.
Johnson & Johnson plans to restructure its orthopedic business and exit certain markets after lower-than-expected third-quarter sales, while increasing its annual profit forecast due to strong pharmaceutical business sales and the success of the arthritis drug Stelara.
